The pharmacological treatment options for acromegaly can be categorized into three main groups: somatostatin receptor ligands (SRLs), which are recommended as the first-line treatment for patients who are not candidates for surgery; growth hormone receptor (GH) antagonists, which serve as adjunctive therapy for severe cases beyond the first-line treatment; and dopamine agonists (DAs), which are used as adjunctive therapy for mild cases (15, 21, 22). The gene discussed is GH1; the disease is acromegaly.